Technology ID
TT-0101
Description
Our AI-driven drug screening platform utilizes deep learning algorithms to classify cell status and evaluate drug efficacy based on images, enabling rapid, cost-effective drug discovery for complex diseases lacking ideal screening markers.
Content
High Accuracy: Our platform has >99% accuracy for cell status classification. Multiple pipelines including idiopathic pulmonary fibrosis (IPF) and Leigh Syndrome have been established and validated
High Versatility: Our platform can be applied to diseases with unknown MOA
Proven In-House Pipeline: From in vitro screening to animal validation, our pipeline has successfully generated lead compounds for IPF
Inventors
Applicable Industries
Potential Application
Technology Focus
TRL
Images
